Поиск по каталогу |
(строгое соответствие)
|
- Профессиональная
- Научно-популярная
- Художественная
- Публицистика
- Детская
- Искусство
- Хобби, семья, дом
- Спорт
- Путеводители
- Блокноты, тетради, открытки
Atherogenic Dyslipidemia Index. A helpful marker for detecting primary care patients with high cardiometabolic risk
В наличии
Местонахождение: Алматы | Состояние экземпляра: новый |
Бумажная
версия
версия
Автор: Katarzyna Anna Rygiel
ISBN: 9783659392672
Год издания: 2013
Формат книги: 60×90/16 (145×215 мм)
Количество страниц: 52
Издательство: LAP LAMBERT Academic Publishing
Цена: 20988 тг
Положить в корзину
Способы доставки в город Алматы * комплектация (срок до отгрузки) не более 2 рабочих дней |
Самовывоз из города Алматы (пункты самовывоза партнёра CDEK) |
Курьерская доставка CDEK из города Москва |
Доставка Почтой России из города Москва |
Аннотация: Innovative instruments to stem the tide of cardiometabolic diseases are needed, especially in primary care (PC). A measurement of the ratio: triglycerides (TG) to HDL-Cholesterol (HDL-C), known as atherogenic dyslipidemia index (TG/HDL-C) (a biomarker of plasma atherogenicity & insulin resistance), may be helpful in PC, since it can shed some light on early detection of asymptomatic patients with high cardiovascular (CV) risk. This work explores the correlations between TG/HDL-C, lipid and anthropometric parameters, coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM), in PC patients. This analysis reports that the increased TG/HDL-C positively correlates with obesity and diabetes. Thus, TG/HDL-C may serve as a simple tool for the identification of patients, who may be at high risk for CHD or diabetes, despite achieving the recommended LDL-C levels. This book, therefore, proposes TG/HDL-C as a novel marker, which should be useful to PC practitioners, cardiology and diabetology specialists, pharmacists, dietitians, nurses, rehabilitants, and health educators. Also, researchers may consider this marker for future design of prospective randomized clinical trials.
Ключевые слова: Obesity, Coronary Heart Disease (CHD), Central obesity, atherogenic dyslipidemia, type 2 diabetes mellitus (T2DM), cardiovascular (CV) risk